Status:
COMPLETED
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Lead Sponsor:
Human Genome Sciences Inc., a GSK Company
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B...
Detailed Description
This is a long-term continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States. This study is to evaluate the long-term safety and efficacy o...
Eligibility Criteria
Inclusion
- Have completed the HGS1006-C1056 protocol in the United States through Week 72 visit.
- Be able to receive 1st dose of belimumab for HGS 1006-c1066 four weeks after last dose in HGS1006-c1056.
Exclusion
- Have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
268 Patients enrolled
Trial Details
Trial ID
NCT00724867
Start Date
August 1 2008
End Date
March 1 2015
Last Update
March 28 2016
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Birmingham, Alabama, United States, 35249
2
GSK Investigational Site
Phoenix, Arizona, United States, 85032
3
GSK Investigational Site
Tucson, Arizona, United States, 85724
4
GSK Investigational Site
Long Beach, California, United States, 90806